Conflicts of interest Dr. N. Deltour is an employee of I.R.I.S (Institut de Recherche International Servier). Dr. Jean-Yves Reginster has the following conflicts: Consulting fees or paid advisory boards – Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB; Lecture fees when speaking at the invitation of a commercial sponsor – Merck Sharp & Dohme, Lilly, Rottapharm,

IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk; Grant Support from Industry – Bristol Myers RO4929097 mw Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) www.selleckchem.com/products/c188-9.html and source are credited. References

1. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, Becker RC, Goldberg RJ (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722–727CrossRefPubMed 2. Rosendaal FR, Van Hylckama Vlieg A, Doggen CJ (2007) Venous thrombosis in the elderly. J Thromb Haemost 5(Suppl 1):310–317CrossRefPubMed 3. Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP (2007) Venous thrombosis in the elderly: more questions than answers. Blood 110:3097–3101CrossRefPubMed 4. Kuehn BM (2008) New tool measures 10-year fracture risk. JAMA 299:1651–1652CrossRefPubMed 5. Guessous I, Cornuz J, Ruffieux C, Burckhardt P, Krieg MA (2008) Osteoporotic

fracture risk in elderly women: Adenosine estimation with quantitative heel US and clinical risk factors. Radiology 248:179–184CrossRefPubMed 6. Cheung AM, Detsky AS (2008) Osteoporosis and fractures: missing the bridge? JAMA 299:1468–1470CrossRefPubMed 7. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRefPubMed 8. Maclaughlin EJ, Sleeper RB, McNatty D, Raehl CL (2006) Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag 2:281–295CrossRefPubMed 9. Roux C (2008) Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis. Rheumatology (Oxford) 47(Suppl 4):iv20–iv22CrossRef 10. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic Selleck Semaxanib review. Osteoporos Int 15:767–778CrossRefPubMed 11. EMEA (2008) SPC: summary product characteristics (EMEA 2008) 12. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.